ClinicalTrials.gg
Status unknownNCT04890587Updated May 18, 2021

A Phase I Study of AL8326 in Advanced Solid Tumor

A Phase 1 interventional study of AL8326 tablets in Advanced Solid Tumors, sponsored by Advenchen Laboratories Nanjing Ltd.. Status unknown at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-05-18.

Sponsored by Advenchen Laboratories Nanjing Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 years 8 months after the study started (first participant enrolled Aug 2017, registered Apr 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

  1. Main purpose Objective to study the tolerance and safety of single and multiple administration of repeated 28-day cycles of AL8326 in patients with advanced solid tumor, observe the dose limiting toxicity (DLT) and maximum tolerated dose (MTD).
  2. Secondary purpose 1) Preliminary analysis of the pharmacokinetic characteristics and efficacy of repeated 28-day cycles of AL8326 tablets in patients with advanced solid tumors; 2) According to the results of phase I tolerance test and pharmacokinetics, appropriate dosage and regimen were recommended for phase II clinical trial;
Read the detailed description

This is a Phase 1 study to evaluate the safetyand efficacy of 28-day cycles of AL8326 therapy. The study is divided into three parts.

  1. Part I To evaluate the dose limiting toxicity (DLT) and general safety during the first 28-day cycle of Al8326 therapy and to evaluate the MTD. It will include a evaluation of 3 subjects per cohort in a 3+3 design in.
  2. Part II Subject will receive a dose from Part 1 of this study for continuous 28-Day cycles of therapy.
  3. Part III This design adopts 3 + 3 dose de-escalation method for exploration. At the same time, the safety, tolerance and pharmacokinetics were observed.
02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Maximum tolerated dose
  • Dose limiting toxicity
03

In context

Lead sponsor

Advenchen Laboratories Nanjing Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with the following advanced solid tumors confirmed by histology or cytology (including but not limited to non-small cell lung cancer, cervical cancer, ovarian cancer, breast cancer, pancreatic cancer, liver cancer, colon cancer, head and neck cancer, prostate cancer, kidney cancer, etc.). Lack of effective standard treatment options; or failure (including disease progression or intolerance) or recurrence after conventional standard treatment.
  2. For subject received cytotoxic drugs chemotherapy before, the interval between the end of chemotherapy and the signing of was at least 4 weeks, and must be recovered from the toxic reaction of previous chemotherapy to ≤ 1 grade (except for hair loss);
  3. There must be at least in accordance with 1.1. If there is only one lesion, the lesion must be confirmed by cytology / histology.
  4. Main organ function:

    1. (ANC) ≥ 1.5 × 10 \^ 9 / L (1500 / mm \^ 3), ≥ 75 × 10 \^ 9 / L or ≥ 9g / dl.
    2. Serum total ≤ 2 times the upper limit .
    3. Serum creatinine ≤ 1.5 times the value or rate ≥ 50ml / min.
    4. If there is no liver , (ALT) or aspartate aminotransferase (AST) ≤ 2.5 times of the upper limit, or liver metastasis ≤ 5 times of the upper limit .
    5. Doppler ultrasound evaluation: (LVEF) ≥ 50%.
    6. According to the judgment of the investigator, the laboratory examination results and clinical abnormalities that will not affect the safety of the subjects and the completion of the trial can be arranged into the group.
  5. (PS) score was 0,1;
  6. ≥ 12 weeks;
  7. Age ≥ 18 years old and ≤ 70 years old;
  8. There was no malabsorption or other gastrointestinal diseases affecting drug absorption.
  9. Female: for female patients with fertility, pregnancy test must be conducted before treatment, and method approved by medical department must be adopted during treatment and within 3 months after treatment; serum or urine pregnancy test in screening period must be negative; it must be non lactation period; and;if a female patient is but has not yet reached the postmenopausal state (the duration of menopause is greater than or equal to 12 consecutive months, and there is no other reason except menopause), and has not received sterilization surgery (removal of ovaries and / or uterus), she is considered to be fertile.
  10. Male: during surgical sterilization or treatment and within 3 months after the end of the treatment, the contraceptive measures approved by the doctor were adopted;
  11. Ability to understand and sign informed consent.

Exclusion criteria

Exclusion Criteria:

  1. It is known that it is allergic to drugs with similar chemical structure.
  2. Use of drugs or other trial drugs without approval within 30 days before enrollment.
  3. The condition of each organ system was as follows:

    1. Patients with previous history of central nervous system or uncontrollable symptoms of , spinal cord compression and cancerous meningitis within 8 weeks after the first administration. For patients with CNS metastasis or spinal cord compression, if the clinical status is stable and does not need hormone therapy, and the interval between the treatment (including radiotherapy or surgery) before entering the group is more than 4 weeks, they can participate in this trial.
    2. Grade 2 or above hypertension that cannot be controlled by single drug.
    3. Acute myocardial infarction occurred within 6 months.
    4. At present, there are arrhythmias (such as long syndrome, unmeasurable or ≥ 480ms of Bazett's corrected QTC).
    5. cardiac function grade III or IV.
    6. Evidence of severe or uncontrollable systemic disease (e.g., unstable or decompensated respiratory, heart, liver, or kidney disease), as judged by the investigators.
    7. Any unstable systemic disease (including active infection, angina pectoris, liver and kidney or metabolic disease, etc.).
    8. Other (primary) (except for completely cured cervical carcinoma in situ or basal cell carcinoma or squamous cell skin carcinoma) within five years.
    9. The presence of clinically detectable third space effusion (such as ascites or pleural effusion) requires immediate drainage. Or after treatment, the effusion is not well controlled and continues to increase.
    10. Previous history of definite neurological or mental disorders, such as epilepsy or dementia.
  4. The function level of each organ was as follows:

    1. The results of urine protein analysis showed that urine protein was ≥ + +, and 24-hour urine protein was more than 1.0 g.
    2. Coagulation dysfunction: Patients with bleeding tendency (such as active peptic ulcer) or undergoing thrombolytic or anticoagulant therapy; under the premise of international normalized ratio (INR) ≤ 1.5, it is allowed to use low-dose warfarin (1mg oral, once a day) or low-dose aspirin (less than 100mg daily) for preventive purposes.
    3. Patients with arteriovenous thrombosis events within 6 months, such as cerebrovascular accident (including ), deep venous thrombosis and pulmonary embolism.
  5. The patients who had been enrolled before who had withdrawn from this study.
  6. antibody is positive, or the patient has other acquired or congenital immunodeficiency disease, or has a history of organ transplantation.
  7. At the same time, they received any other anti-tumor treatment.
  8. The researcher thinks that it is not suitable to participate in this study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    AL8326

    Part 1:(closed)Cohort 1 will initiate with AL8326 for single dose and multiple dose (28-Day cycles) . After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, several additional cohorts will be sequentially for the same 28-day cycles. Part 2 :(open)Each subject will receive a dose from Part 1 of this study for continuous 28-Day cycles of therapy. Part 3:(open)Cohort 3 will initiate with AL8326(bid), for 28-Day cycles . After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, two additional cohorts will be sequentially enrolled at decreased dose of AL8326 for the same 28-day cycles.

    Drug: AL8326 tablets

Interventions

  • Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.

    Also known as: AL8326

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    To observe the durability and safety of AL8326 in patients with advanced solid tumor after single and multiple administration, observe the dose limiting toxicity (DLT)and the reversibility of toxicity;

    Time frame: cycle1 (each cycle is 28-days)

  2. Maximum tolerated dose (MTD)

    To observe the durability and safety of AL8326 in patients with advanced solid tumor after single and multiple administration, observe the maximum tolerated dose (MTD),the relationship between toxicity and dose;

    Time frame: cycle1 (each cycle is 28-days)

Secondary outcomes

  1. Cmax

    The pharmacokinetic characteristics of Al8326 tablets in patients with advanced solid tumor were analyzed;

    Time frame: cycle1 (each cycle is 28-days)

  2. Tmax

    The pharmacokinetic characteristics of Al8326 tablets in patients with advanced solid tumor were analyzed;

    Time frame: cycle1 (each cycle is 28-days)

  3. AUC0-t

    The pharmacokinetic characteristics of Al8326 tablets in patients with advanced solid tumor were analyzed;

    Time frame: cycle1 (each cycle is 28-days)

  4. AUC0-∞

    The pharmacokinetic characteristics of Al8326 tablets in patients with advanced solid tumor were analyzed;

    Time frame: cycle1 (each cycle is 28-days)

  5. Vd

    The pharmacokinetic characteristics of Al8326 tablets in patients with advanced solid tumor were analyzed;

    Time frame: cycle1 (each cycle is 28-days)

  6. Ke

    The pharmacokinetic characteristics of Al8326 tablets in patients with advanced solid tumor were analyzed;

    Time frame: cycle1 (each cycle is 28-days)

  7. CL

    The pharmacokinetic characteristics of Al8326 tablets in patients with advanced solid tumor were analyzed;

    Time frame: cycle1 (each cycle is 28-days)

  8. t1/2

    The pharmacokinetic characteristics of Al8326 tablets in patients with advanced solid tumor were analyzed;

    Time frame: cycle1 (each cycle is 28-days)

  9. Primary antitumor efficiency of AL8326

    Patients with advanced solid tumors and their efficacy in patients with advanced solid tumors were evaluated according to RECIST 1.1.

    Time frame: Every 3 cycles(each cycle is 28-days)

07

Study locations

2 of 2 sites recruiting
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
    Recruiting
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2017 (actual). Primary completion is estimated for Dec 2023, 76 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2021
First posted
May 18, 2021
StartActual
Aug 17, 2017
Primary completionEst.
Dec 2023
CompletionEst.
Dec 2023
Last update
May 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04890587
Lead sponsor
Advenchen Laboratories Nanjing Ltd.
Responsible party
Sponsor
First posted
May 18, 2021
Start date
Aug 17, 2017
Primary completion
Dec 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
May 18, 2021

Study contacts

Yingyin Li
Contact
annel@advenchen.com
+8657188683590
Huaqing He
Contact
huaqingh@advenchen.com
+8615205140516
Nong Yang
principal investigator · Central organization

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aurora B/VEGFR/FGFR Inhibitor AL8326

Start the discussion